iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 1655

Identifiers

  • Canonical SMILES: 
    Cc1ccc(cc1NC(=S)NC(=O)c1ccc2OCCOc2c1)-c1nc2ccccc2[nH]1
  • IUPAC name: 
    3-[5-(1H-1,3-benzodiazol-2-yl)-2-methylphenyl]-1-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)thiourea
  • InChi: 
    InChI=1S/C24H20N4O3S/c1-14-6-7-15(22-25-17-4-2-3-5-18(17)26-22)12-19(14)27-24(32)28-23(29)16-8-9-20-21(13-16)31-11-10-30-20/h2-9,12-13H,10-11H2,1H3,(H,25,26)(H2,27,28,29,32)
  • InChiKey: 
    BVWHOZYQECWMFG-UHFFFAOYSA-N

External links


1254374
CHEMBL3322197

External search

Bibliography (1)

Publication Name
Borriello L, Montès M, Lepelletier Y, Leforban B, Liu WQ, Demange L, Delhomme B, Pavoni S, Jarray R, Boucher JL, Dufour S, Hermine O, Garbay C, Hadj-Slimane R, Raynaud F. . Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model. Cancer letters. 1

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 2 1 0

Targets

PPI family Best activity Diseases MMoA
NRP / VEGF 6.70 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 444.13 g/mol
HBA 7
HBD 3
HBA + HBD 10
AlogP 4.46
TPSA 88.27
RB 3
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 1 2 1 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
24752068 1 NRP1
Q9QWJ9
Biochemical assay chemiluminescent pIC50 (half maximal inhibitory concentration, -log10) 4.47
24752068 1 NRP1
Q9QWJ9
Cellular assay HUVEC proliferation HUVEC pIC50 (half maximal inhibitory concentration, -log10) 6.70
24752068 1 NRP1
Q9QWJ9
Cellular assay MDA-MB-231 proliferation MDA-MB-231 pIC50 (half maximal inhibitory concentration, -log10) 6.22
PK data
Bibliography Name Assay name Administration mode Dose (mg/kg) Dose interval (hours) Tolerated AUC Clearance Cmax Oral bioavailability T1/2 (min) Tmax (min) Volume distribution (Vd)
24752068 1 MDA-MB-231-xenografted NOG mice PO 10000.00 None yes no no no None None None no
Ta Structure Name Drugbank ID
0.4667 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide DB04010
0.4593 Nemorexant DB15031
0.4578 CRA_10656 DB04470
0.4564 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide DB06938
0.4468 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID DB04644
0.4451 CRA_10655 DB02526
0.4426 CM-4307 DB15414
0.4426 Sorafenib DB00398
0.4413 N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE DB08066
0.4379 N-(TERT-BUTYL)-3,5-DIMETHYL-N'-[(5-METHYL-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)CARBONYL]BENZOHYDRAZIDE DB07929
0.4358 Piclamilast DB01791
0.4277 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE DB07459
0.4250 E-6005 DB12776
0.4239 Roflumilast DB01656
0.4231 6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine DB06855